---
title: Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
nct_id: NCT02936206
overall_status: TERMINATED
phase: PHASE1
sponsor: Icahn School of Medicine at Mount Sinai
study_type: INTERVENTIONAL
primary_condition: Breast Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02936206.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02936206"
ct_last_update_post_date: 2021-05-19
last_seen_at: "2026-05-12T06:40:47.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

**Official Title:** Comparison in the Change of Proliferation Index Between Fulvestrant and Tamoxifen in Cyclin D1 +, Estrogen Receptor + Breast Cancer

**NCT ID:** [NCT02936206](https://clinicaltrials.gov/study/NCT02936206)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** low accrual rate
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 2
- **Lead Sponsor:** Icahn School of Medicine at Mount Sinai
- **Collaborators:** AstraZeneca
- **Conditions:** Breast Cancer
- **Start Date:** 2016-10
- **Completion Date:** 2020-05-01
- **CT.gov Last Update:** 2021-05-19

## Brief Summary

The purpose of this study is to microscopically examine breast cancer cells of pre-menopausal and post-menopausal women before and after exposure to one of the two commonly used breast cancer drugs, tamoxifen or fulvestrant.

## Detailed Description

The researchers hypothesize that the cyclinD1-interactome can be used to orient the use of fulvestrant in premenopausal and postmenopausal women. To test this hypothesis, the researchers propose a pre-surgical randomized clinical trial of tamoxifen vs fulvestrant in the window between breast cancer diagnosis on core biopsy and definitive surgery. Women with ER/cyclinD1 positive tumors will be eligible. Response to tamoxifen or fulvestrant will be evaluated using standard proliferation index as well as gene expression signatures obtained in pre-clinical models of tamoxifen resistance and sensitivity to fulvestrant. In addition, the researchers propose to use cutting edge new technology allowing ex-vivo expansion of primary culture from only a few cancer cells obtained by fine needle biopsy. The researchers propose to compare the response of these primary cells to patient response. If successful, the impact of this work can support the expansion of use of fulvestrant to not only postmenopausal women but premenopausal women as well. In addition, it may serve as a proof of principle to maximize the use of biopsy material to predict treatment response

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the study treatment regimen and follow-up, must be obtained and documented according to the local regulatory requirements
* Adult women greater than 18 years old
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
* New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer

  * Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater
  * Hormone receptor positive as defined as ≥ 10% positive stained cells
  * HER2-normal (IHC score 0-1 or FISH negative \[in-situ hybridization (ISH) ratio \<= 2.0 status\])
* Tumor size at least 5 mm with planned primary surgery at Mount Sinai
* A negative urine dipstick pregnancy test

Exclusion Criteria:

* Estrogen receptor negative invasive breast carcinoma as defined as less than 10% stained cells
* Prior antiestrogen therapy
* Tumor size less than 5 mm
* Prior diagnosis of thrombosis or known hypercoagulable state
* Known history of bleeding diathesis
* Known liver disease
* Prior treatment with neoadjuvant therapy
* Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema).
* Current severe or uncontrolled systemic disease
* Pregnancy or lactation period. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices) during study treatment.
* Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.
```

## Arms

- **Fulvestrant** (EXPERIMENTAL) — 750 mg injection in 3 divided doses
- **Tamoxifen** (ACTIVE_COMPARATOR) — 20mg orally

## Interventions

- **Fulvestrant** (DRUG) — fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
- **Tamoxifen** (DRUG) — 14 days of treatment with tamoxifen 20mg orally each day

## Primary Outcomes

- **Change in Ki67 Cell Percentage** _(time frame: baseline and 2 weeks)_ — The change in proliferation index as measured by the percentage of cells staining for Ki67 at 2 weeks as compared on baseline.

## Secondary Outcomes

- **Change in Estrogen Receptor Level** _(time frame: baseline and 2 weeks)_
- **Change in Progesterone Receptor Level** _(time frame: baseline and 2 weeks)_
- **Incidence of Tamoxifen-resistance Gene Expression** _(time frame: 2 weeks)_
- **Incidence of Fulvestrant-sensitivity Gene Expression** _(time frame: 2 weeks)_
- **Drug Dose Level** _(time frame: 2 weeks)_
- **Percentage of Cells Staining Positive Within the Breast Tumor** _(time frame: 2 weeks)_

## Locations (3)

- Mount Sinai West, New York, New York, United States
- Mount Sinai St. Luke's, New York, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mount sinai west|new york|new york|united states` — added _(2026-05-12)_
- `locations.mount sinai st. luke's|new york|new york|united states` — added _(2026-05-12)_
- `locations.icahn school of medicine at mount sinai|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02936206.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02936206*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*